Immunogen Inc (IMGN)

2.78
NASDAQ : Health Care
Prev Close 2.79
Day Low/High 2.71 / 2.79
52 Wk Low/High 2.68 / 18.78
Avg Volume 2.32M
Exchange NASDAQ
Shares Outstanding 87.08M
Market Cap 242.94M
EPS -0.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

First Week of August 19th Options Trading For ImmunoGen (IMGN)

First Week of August 19th Options Trading For ImmunoGen (IMGN)

Investors in ImmunoGen, Inc. saw new options become available this week, for the August 19th expiration.

ImmunoGen Announces Pricing Of $100 Million Offering Of 4.50% Convertible Senior Notes Due 2021

ImmunoGen Announces Pricing Of $100 Million Offering Of 4.50% Convertible Senior Notes Due 2021

ImmunoGen, Inc. (NASDAQ: IMGN) today announced the pricing of $100 million aggregate principal amount of its 4.

ImmunoGen Announces Proposed $100 Million Offering Of Convertible Senior Notes Due 2021

ImmunoGen Announces Proposed $100 Million Offering Of Convertible Senior Notes Due 2021

ImmunoGen, Inc. (NASDAQ: IMGN) today announced its intention to offer and sell to the initial purchasers, subject to market and other conditions, $100 million aggregate principal amount of convertible senior notes due 2021...

ImmunoGen Becomes Oversold (IMGN)

ImmunoGen Becomes Oversold (IMGN)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Immunogen (IMGN) Weak On High Volume

Immunogen (IMGN) Weak On High Volume

Trade-Ideas LLC identified Immunogen (IMGN) as a weak on high relative volume candidate

5 Breakout Stocks Under $10 Set to Soar

5 Breakout Stocks Under $10 Set to Soar

These under-$10 stocks are within range of triggering big breakout trades.

ImmunoGen Reports Efficacy And Safety Data From A 46-Patient Cohort Of Mirvetuximab Soravtansine In FRa-Positive Ovarian Cancer

ImmunoGen Reports Efficacy And Safety Data From A 46-Patient Cohort Of Mirvetuximab Soravtansine In FRa-Positive Ovarian Cancer

ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company developing novel antibody-drug conjugate (ADC) cancer therapeutics, today reported the clinical data from a 46-patient Phase 1 cohort evaluating the...

ImmunoGen, Inc. Announces Webcasts Of Presentations At Upcoming Investor Conferences

ImmunoGen, Inc. Announces Webcasts Of Presentations At Upcoming Investor Conferences

ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company developing targeted cancer therapeutics using its proprietary antibody-drug conjugate (ADC) technology, today announced that the following presentations by Company...

Relative Strength Alert For ImmunoGen

Relative Strength Alert For ImmunoGen

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Immunogen (IMGN): Today's Weak On High Volume Stock

Immunogen (IMGN): Today's Weak On High Volume Stock

Trade-Ideas LLC identified Immunogen (IMGN) as a weak on high relative volume candidate

ImmunoGen Reports Third Quarter Fiscal Year 2016 Financial Results And Provides Corporate Update

ImmunoGen Reports Third Quarter Fiscal Year 2016 Financial Results And Provides Corporate Update

ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company developing targeted cancer therapeutics using its proprietary ADC technology, today reported financial results for the three-month period ended March 31, 2016 - the...

ImmunoGen Appoints Mark J. Enyedy As President And Chief Executive Officer

ImmunoGen Appoints Mark J. Enyedy As President And Chief Executive Officer

ImmunoGen, Inc. (Nasdaq: IMGN) a biotechnology company developing targeted cancer therapeutics using its proprietary antibody-drug conjugate (ADC) technology, today announced that Mark J.

ImmunoGen Announces Initiation Of Clinical Testing Of First-in-Class IMGN779 For Acute Myeloid Leukemia

ImmunoGen Announces Initiation Of Clinical Testing Of First-in-Class IMGN779 For Acute Myeloid Leukemia

ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted anticancer therapeutics using its extensive ADC technology portfolio, today announced the start of clinical testing of the Company's IMGN779...

ImmunoGen, Inc. Announces Conference Call To Discuss Its Third Quarter Fiscal Year 2016 Financial Results

ImmunoGen, Inc. Announces Conference Call To Discuss Its Third Quarter Fiscal Year 2016 Financial Results

ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the Company will host a conference call at...

Daniel Junius To Retire As President And CEO Of ImmunoGen, Inc.

Daniel Junius To Retire As President And CEO Of ImmunoGen, Inc.

ImmunoGen, Inc. (Nasdaq: IMGN) a biotechnology company that develops targeted anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that Daniel Junius, age 63, has decided to...

ImmunoGen, Inc. Announces Presentations At Upcoming AACR Annual Meeting

ImmunoGen, Inc. Announces Presentations At Upcoming AACR Annual Meeting

ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced the presentations related to the Company's...

Interesting IMGN Put And Call Options For May 20th

Interesting IMGN Put And Call Options For May 20th

Investors in ImmunoGen, Inc. saw new options become available this week, for the May 20th expiration.

8 Biotech Stocks Under $10 Making Big Moves Higher

8 Biotech Stocks Under $10 Making Big Moves Higher

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Today's Weak On High Volume Stock: Immunogen (IMGN)

Today's Weak On High Volume Stock: Immunogen (IMGN)

Trade-Ideas LLC identified Immunogen (IMGN) as a weak on high relative volume candidate

ImmunoGen And Merck Establish Collaboration For Clinical Evaluation Of Mirvetuximab Soravtansine In Combination With Keytruda® (pembrolizumab) For The Treatment Of Ovarian Cancer

ImmunoGen And Merck Establish Collaboration For Clinical Evaluation Of Mirvetuximab Soravtansine In Combination With Keytruda® (pembrolizumab) For The Treatment Of Ovarian Cancer

ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its ADC technology, and Merck, known as MSD outside the United States and Canada, announced today that they have...

ImmunoGen, Inc. Announces Webcasts Of Presentations At Upcoming Investor Conferences

ImmunoGen, Inc. Announces Webcasts Of Presentations At Upcoming Investor Conferences

ImmunoGen, Inc . (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the following presentations by Company...

Commit To Buy ImmunoGen At $6, Earn 14.8% Annualized Using Options

Commit To Buy ImmunoGen At $6, Earn 14.8% Annualized Using Options

Investors eyeing a purchase of ImmunoGen, Inc. stock, but tentative about paying the going market price of $7.82/share, might benefit from considering selling puts among the alternative strategies at their disposal.

RSI Alert: ImmunoGen (IMGN) Now Oversold

RSI Alert: ImmunoGen (IMGN) Now Oversold

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

ImmunoGen Reports Second Quarter Fiscal Year 2016 Financial Results And Provides Corporate Update

ImmunoGen Reports Second Quarter Fiscal Year 2016 Financial Results And Provides Corporate Update

ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted anticancer therapeutics using its proprietary ADC technology, today reported financial results for the three-month period ended December 31,...

ImmunoGen Earns Milestone With Bayer's Initiation Of A Phase 2 Clinical Study Designed To Support Anetumab Ravtansine Registration

ImmunoGen Earns Milestone With Bayer's Initiation Of A Phase 2 Clinical Study Designed To Support Anetumab Ravtansine Registration

ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced the Company earned a milestone payment with...

ImmunoGen, Inc. Announces Conference Call To Discuss Its Second Quarter Fiscal Year 2016 Financial Results

ImmunoGen, Inc. Announces Conference Call To Discuss Its Second Quarter Fiscal Year 2016 Financial Results

ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the Company will host a conference call at...

Strong On High Volume: Immunogen (IMGN)

Strong On High Volume: Immunogen (IMGN)

Trade-Ideas LLC identified Immunogen (IMGN) as a strong on high relative volume candidate

ImmunoGen Announces Recent Product Program Advancements And Anticipated 2016 Events In Advance Of J.P. Morgan Healthcare Conference

ImmunoGen Announces Recent Product Program Advancements And Anticipated 2016 Events In Advance Of J.P. Morgan Healthcare Conference

ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced recent product program advancements and...